Chiral Technologies Celebrates 20 Years in Advancing Technology
Chiral Technologies, Inc. (West Chester, PA) are celebrating 20 years as the leader in enantioselective chromatography.
Chiral Technologies, Inc. (West Chester, Pennsylvania) are celebrating 20 years as the leader in enantioselective chromatography. In 1990, CTI became the first company to make chiral columns and chiral stationary phases (CSPs) commercially available, "forever changing man's interaction with science and each other."
"After 20 years, we are still dedicated to our goal of enabling researchers to develop single-enantiomer products," said Dieter Heckmann, President and CEO of Chiral Technologies, Inc. "We will continue to pave the way for future discoveries in life science."
According to a press release issued by the company, CTI's columns and CSPs are vital in allowing pharmaceutical and biotech companies go to market faster with their products, and they continue to produce CSPs and columns that have remained among the highest quality in the industry for the past two decades.
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.
